Developments in mast cell research

This review summarizes major advances in mast cell (MC) research published between January 2024 and December 2025. Recent discoveries have reshaped our understanding of MC biology, revealing previously unrecognized roles in brain development, mucosal immunity, neuroimmune communication, and cancer. High-resolution structural studies have provided new insights into FcεRI signaling, while emerging evidence has expanded the functional repertoire of inflammasome components and established Mas-related G-protein coupled receptor member 2 (MRGPRX2) as a central receptor mediating IgE-independent MC activation. Single-cell transcriptomic and spatial profiling studies have uncovered remarkable MC heterogeneity, identifying specialized populations with distinct homeostatic and pathogenic functions across tissues. These findings have also redefined the contribution of MCs to early-life allergic disease, anaphylaxis, pain, infection, and tumor immunity, highlighting their context-dependent functions. In parallel, major therapeutic advances-including antibodies targeting the KIT-stem cell factor axis, next-generation anti-IgE therapies, Bruton tyrosine kinase inhibitors, and strategies targeting type 2 inflammatory pathways-are accelerating the development of more selective treatments for MC-driven disorders. Advances in experimental platforms, including human skin MC cultures, receptor-humanized and humanized mouse models, and computational pathology, are further expanding the tools available to investigate MC biology and accelerate translational research. Together, these conceptual, technological, and therapeutic advances are shaping the next generation of MC-targeted therapies.